The premise of our study was that interleukin-6 receptor blocking, when administered to patients with sickness that had not yet resulted in intubation, would stop the cytokine storm brought on by COVID-19 and avert the worst effects of the disease. This evidence concerns the gene IL6R and COVID-19.